Published human studies on GHK-Cu have examined its role in tissue repair
Key Takeaways Stomach pain on reta is primarily caused by delayed gastric emptying: Retatrutide's GLP-1 receptor activation slows how fast food leaves the stomach, producing cramping, bloating, and abdominal discomfort The triple-agonist mechanism amplifies GI effects: Unlike semaglutide (GLP-1 only) or tirzepatide (GLP-1/GIP), retatrutide hits three receptors GLP-1, GIP, and glucagon creating a broader gastrointestinal impact Abdominal pain affected up to 12% of participants at higher doses: Phase 2 trial data (NEJM, 2023) documented abdominal pain as a distinct adverse event beyond nausea and diarrhea Dose escalation significantly reduces stomach pain incidence: Gradual titration groups reported fewer GI events than participants who started directly at target doses Most stomach pain is transient: Published data shows GI discomfort peaks during the dose-escalation phase and diminishes as the body adjusts at stable doses Severe or persistent abdominal pain requires medical evaluation: Intense, unrelenting belly pain could indicate pancreatitis a rare but serious adverse event documented across all GLP-1 class compounds Why Retatrutide Causes Stomach Pain Stomach pains on reta are the most commonly searched complaint among researchers following this compound and for good reason
)
Classes are interactive, fun, and perfect for all levels
Following a single subcutaneous injection, retatrutide is reported to reach peak plasma concentration (Cmax) within approximately two to three days, though this may vary between individuals and study populations
Gian Paolo Fadini, Angelo Avogaro (Department of Medicine, University of Padova)
Can I use GHK-CU with retinoids
